Akebia and Otsuka partner for vadadustat with a deal worth over US$1 B
By Jawala Prasad
Pharma Deals Review: Vol 2017 Issue 1 (Table of Contents)
Published: 13 Jan-2017
DOI: 10.3833/pdr.v2017.i1.2217 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Akebia Therapeutics has entered into a collaboration and licence agreement with Otsuka to develop and commercialise vadadustat in the US in a deal worth over US$1 B...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS